Trial Profile

A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of Nemolizumab in Adult Patients With Systemic Sclerosis

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 15 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nemolizumab (Primary)
Indications Systemic scleroderma
Focus Proof of concept; Therapeutic Use
Sponsors Galderma

Most Recent Events

09 Jul 2025 Status changed from planning to not yet recruiting.
25 Jun 2025 According to a Galderma media release, Patient enrollment is planned to begin in H2 2025, with completion anticipated in 2028.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com